Trial Profile

Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buspirone/Zolmitriptan (Primary)
Indications Dyskinesias; Parkinson's disease
Focus Adverse reactions
Sponsors Contera Pharma

Most Recent Events

14 Oct 2024 Status changed from recruiting to discontinued.
01 Oct 2023 This study has been completed in France, as per European Clinical Trials Database record
29 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com